A Phase I Study of LOXO-260 in People with Solid Tumors Containing RET Gene Changes


Full Title

A Phase 1 Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors


The RET gene plays a role in the growth and survival of normal cells, but a change in the gene may fuel the growth of cancer cells. In this study, researchers are finding the highest dose of the investigational drug LOXO-260 that can be given safely in people with solid tumors that continue to grow despite treatment and contain changes in the RET gene. LOXO-260 blocks the RET protein (which is made by the RET gene), and this blocking action may slow or stop cancer growth. LOXO-260 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have an inoperable or metastatic solid tumor that has continued to grow despite treatment and contains either a mutation or a fusion (when parts of two different genes are joined together) in the RET gene.
  • Patients may have previously received another RET inhibitor.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Drilon at 646-608-3758.




Phase I (phase 1)




ClinicalTrials.gov ID